The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SYBX | +19.12% | -94.76% | -44.55% | -99% |
| S&P | +12.26% | +86.71% | +13.3% | +172% |
Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Gross Margin | -16087.50% | 0.0% |
| Market Cap | $19.51M | 12.0% |
| Market Cap / Employee | $19.51M | 0.0% |
| Employees | 1 | -83.3% |
| Net Income | -$2.30M | -1866.7% |
| EBITDA | -$0.83M | -82.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $15.59M | -19.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -17.30% | 84.3% |
| Return On Invested Capital | -93.21% | -37.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.44M | -121.3% |
| Operating Free Cash Flow | -$1.44M | -121.3% |
| Metric | Q1 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 10.58 | - | |||
| Price to Book | 1.25 | 1.14 | 1.13 | 1.55 | 42.09% |
| Price to Sales | 6.78 | 5.87 | 6.56 | 2046.82 | 20925.97% |
| Price to Tangible Book Value | 1.25 | 1.14 | 1.13 | 1.55 | 42.09% |
| Enterprise Value to EBITDA | 1.78 | 2.23 | 1.76 | -6.00 | -330.81% |
| Return on Equity | -109.7% | 11.3% | -7.3% | -27.5% | -82.39% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
